drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00397 | DB00561 | 1,466 | 1,048 | [
"DDInter1458",
"DDInter591"
] | Phenylpropanolamine | Doxapram | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225) | Moderate | 1 | [
[
[
1466,
24,
1048
]
],
[
[
1466,
21,
28963
],
[
28963,
60,
1048
]
],
[
[
1466,
24,
532
],
[
532,
63,
1048
]
],
[
[
1466,
35,
584
],
[
584... | [
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxapram"
]
],
[
[
"Phenylpropanolamine",
"{u} (Compound) causes {v} (Side Effect)",
"Anxiety"
],
[
"Anxiety",
"{u} (Side Eff... | Phenylpropanolamine (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Doxapram (Compound)
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Dobutamine and Dobutamine may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00425 | DB08820 | 558 | 1,478 | [
"DDInter1970",
"DDInter997"
] | Zolpidem | Ivacaftor | Zolpidem, also known as _Ambien_, is a hypnotic drug that was initially approved by the FDA in 1992 [FDA label]. Zolpidem improves sleep in patients with insomnia. It is aimed for use in patients with difficulties initiating sleep. This drug decreases the time to fall asleep (sleep latency), increases the duration of s... | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
558,
24,
1478
]
],
[
[
558,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
558,
21,
29221
],
[
29221,
60,
1478
]
],
[
[
558,
24,
1040
],
[
1040,... | [
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Zolpidem",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Zolpidem (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Zolpidem (Compound) causes Infestation (Side Effect) and Infestation (Side Effect) is caused by Ivacaftor (Compound)
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafen... |
DB01157 | DB14444 | 304 | 151 | [
"DDInter1875",
"DDInter924"
] | Trimetrexate | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect. | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Moderate | 1 | [
[
[
304,
24,
151
]
],
[
[
304,
63,
66
],
[
66,
24,
151
]
],
[
[
304,
24,
850
],
[
850,
24,
151
]
],
[
[
304,
25,
375
],
[
375,
24,
... | [
[
[
"Trimetrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Trimetrexate",
"{u} may cause a moderate interaction that cou... | Trimetrexate may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Trimetrexate may cause a moderate i... |
DB00970 | DB01155 | 0 | 872 | [
"DDInter466",
"DDInter813"
] | Dactinomycin | Gemifloxacin | A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also d... | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | Minor | 0 | [
[
[
0,
23,
872
]
],
[
[
0,
23,
739
],
[
739,
1,
872
]
],
[
[
0,
62,
1299
],
[
1299,
1,
872
]
],
[
[
0,
23,
945
],
[
945,
40,
8... | [
[
[
"Dactinomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gemifloxacin"
]
],
[
[
"Dactinomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
],
... | Dactinomycin may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gemifloxacin (Compound)
Dactinomycin may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin and Trovafloxacin (Compound) resembles Gemifloxac... |
DB01033 | DB01042 | 328 | 1,307 | [
"DDInter1156",
"DDInter1144"
] | Mercaptopurine | Melphalan | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-con... | Moderate | 1 | [
[
[
328,
24,
1307
]
],
[
[
328,
5,
11555
],
[
11555,
44,
1307
]
],
[
[
328,
21,
28787
],
[
28787,
60,
1307
]
],
[
[
328,
23,
956
],
[
956,... | [
[
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
]
],
[
[
"Mercaptopurine",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} ... | Mercaptopurine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Melphalan (Compound)
Mercaptopurine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Melphalan (Compound)
Mercaptopurine may cause a minor interaction that can limit clinical ... |
DB09280 | DB12001 | 1,604 | 564 | [
"DDInter1101",
"DDInter7"
] | Lumacaftor | Abemaciclib | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Major | 2 | [
[
[
1604,
25,
564
]
],
[
[
1604,
64,
868
],
[
868,
24,
564
]
],
[
[
1604,
25,
982
],
[
982,
63,
564
]
],
[
[
1604,
25,
1297
],
[
1297,
... | [
[
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abemaciclib"
]
],
[
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u... | Lumacaftor may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Lumacaftor may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate i... |
DB01242 | DB11718 | 1,237 | 927 | [
"DDInter410",
"DDInter640"
] | Clomipramine | Encorafenib | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
1237,
24,
927
]
],
[
[
1237,
62,
112
],
[
112,
23,
927
]
],
[
[
1237,
40,
216
],
[
216,
24,
927
]
],
[
[
1237,
24,
659
],
[
659,
... | [
[
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Clomipramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Clomipramine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Clomipramine (Compound) resembles Chlorpromazine (Compound) and Chlorpromazine may cause a moderate interac... |
DB00188 | DB00673 | 168 | 723 | [
"DDInter222",
"DDInter112"
] | Bortezomib | Aprepitant | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Moderate | 1 | [
[
[
168,
24,
723
]
],
[
[
168,
24,
875
],
[
875,
40,
723
]
],
[
[
168,
6,
7950
],
[
7950,
45,
723
]
],
[
[
168,
21,
28890
],
[
28890,
... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
],
[... | Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant and Fosaprepitant (Compound) resembles Aprepitant (Compound)
Bortezomib (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Aprepitant (Compound)
Bortezomib (Compound) causes Myocardial infarction (Side Eff... |
DB11703 | DB14444 | 405 | 151 | [
"DDInter9",
"DDInter924"
] | Acalabrutinib | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Moderate | 1 | [
[
[
405,
24,
151
]
],
[
[
405,
63,
66
],
[
66,
24,
151
]
],
[
[
405,
24,
1619
],
[
1619,
24,
151
]
],
[
[
405,
64,
1468
],
[
1468,
2... | [
[
[
"Acalabrutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Acalabrutinib",
"{u} may cause a moderate interaction that c... | Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Acalabrutinib may cause a moderate... |
DB00594 | DB01050 | 863 | 848 | [
"DDInter68",
"DDInter900"
] | Amiloride | Ibuprofen | A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions... | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Moderate | 1 | [
[
[
863,
24,
848
]
],
[
[
863,
24,
1053
],
[
1053,
1,
848
]
],
[
[
863,
21,
28929
],
[
28929,
60,
848
]
],
[
[
863,
62,
752
],
[
752,
... | [
[
[
"Amiloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Amiloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
],
[
... | Amiloride may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine (Compound) resembles Ibuprofen (Compound)
Amiloride (Compound) causes Confusional state (Side Effect) and Confusional state (Side Effect) is caused by Ibuprofen (Compound)
Amiloride may cause a minor ... |
DB08904 | DB13007 | 375 | 1,060 | [
"DDInter342",
"DDInter642"
] | Certolizumab pegol | Enfortumab vedotin | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protea... | Major | 2 | [
[
[
375,
25,
1060
]
],
[
[
375,
63,
1593
],
[
1593,
24,
1060
]
],
[
[
375,
25,
270
],
[
270,
24,
1060
]
],
[
[
375,
64,
350
],
[
350,
... | [
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],... | Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Certolizumab pegol may lead to a major life threatening interaction when taken with Ocrelizumab ... |
DB00747 | DB00850 | 1,442 | 1,630 | [
"DDInter1647",
"DDInter1432"
] | Scopolamine | Perphenazine | Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient ... | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Moderate | 1 | [
[
[
1442,
24,
1630
]
],
[
[
1442,
63,
252
],
[
252,
40,
1630
]
],
[
[
1442,
24,
673
],
[
673,
40,
1630
]
],
[
[
1442,
7,
6952
],
[
6952,
... | [
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyzine"
],
... | Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyzine and Hydroxyzine (Compound) resembles Perphenazine (Compound)
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole and Aripiprazole (Compound) resembles Perphenazine... |
DB00222 | DB00372 | 245 | 999 | [
"DDInter825",
"DDInter1793"
] | Glimepiride | Thiethylperazine | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Moderate | 1 | [
[
[
245,
24,
999
]
],
[
[
245,
24,
460
],
[
460,
62,
999
]
],
[
[
245,
24,
417
],
[
417,
23,
999
]
],
[
[
245,
24,
17
],
[
17,
63,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate and Magnesium carbonate may cause a minor interaction that can limit clinical effects when taken with Thiethylperazine
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB01197 | DB09564 | 1,603 | 1,296 | [
"DDInter292",
"DDInter930"
] | Captopril | Insulin degludec | Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment ... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
1603,
24,
1296
]
],
[
[
1603,
64,
1621
],
[
1621,
23,
1296
]
],
[
[
1603,
25,
948
],
[
948,
62,
1296
]
],
[
[
1603,
63,
1411
],
[
1411... | [
[
[
"Captopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Captopril",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
],
[
... | Captopril may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may cause a minor interaction that can limit clinical effects when taken with Insulin degludec
Captopril may lead to a major life threatening interaction when taken with Potassium gluconate and Potassium... |
DB00501 | DB01050 | 752 | 848 | [
"DDInter380",
"DDInter900"
] | Cimetidine | Ibuprofen | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Minor | 0 | [
[
[
752,
23,
848
]
],
[
[
752,
23,
1307
],
[
1307,
1,
848
]
],
[
[
752,
6,
16560
],
[
16560,
45,
848
]
],
[
[
752,
21,
28929
],
[
28929,
... | [
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ibuprofen"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Melphalan"
],
[
"M... | Cimetidine may cause a minor interaction that can limit clinical effects when taken with Melphalan and Melphalan (Compound) resembles Ibuprofen (Compound)
Cimetidine (Compound) binds SLC22A8 (Gene) and SLC22A8 (Gene) is bound by Ibuprofen (Compound)
Cimetidine (Compound) causes Confusional state (Side Effect) and Confu... |
DB00031 | DB00519 | 20 | 1,638 | [
"DDInter1764",
"DDInter1843"
] | Tenecteplase | Trandolapril | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiote... | Moderate | 1 | [
[
[
20,
24,
1638
]
],
[
[
20,
24,
954
],
[
954,
40,
1638
]
],
[
[
20,
24,
714
],
[
714,
63,
1638
]
],
[
[
20,
24,
1061
],
[
1061,
24... | [
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
]
],
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
],
... | Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) resembles Trandolapril (Compound)
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could... |
DB00405 | DB01100 | 128 | 1,568 | [
"DDInter517",
"DDInter1470"
] | Dexbrompheniramine | Pimozide | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | Moderate | 1 | [
[
[
128,
24,
1568
]
],
[
[
128,
24,
78
],
[
78,
40,
1568
]
],
[
[
128,
6,
3958
],
[
3958,
45,
1568
]
],
[
[
128,
18,
16974
],
[
16974,
... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pimozide"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Droperidol"
... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Droperidol and Droperidol (Compound) resembles Pimozide (Compound)
Dexbrompheniramine (Compound) binds KCNH2 (Gene) and KCNH2 (Gene) is bound by Pimozide (Compound)
Dexbrompheniramine (Compound) downregulates TUBB6 (Gene)... |
DB00477 | DB06589 | 216 | 1,250 | [
"DDInter363",
"DDInter1400"
] | Chlorpromazine | Pazopanib | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
216,
24,
1250
]
],
[
[
216,
6,
7950
],
[
7950,
45,
1250
]
],
[
[
216,
7,
8386
],
[
8386,
46,
1250
]
],
[
[
216,
18,
8954
],
[
8954,
... | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Comp... | Chlorpromazine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Pazopanib (Compound)
Chlorpromazine (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Pazopanib (Compound)
Chlorpromazine (Compound) downregulates HACD3 (Gene) and HACD3 (Gene) is downregulated by Pazopanib (Compound)
Chl... |
DB00346 | DB00372 | 472 | 999 | [
"DDInter44",
"DDInter1793"
] | Alfuzosin | Thiethylperazine | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Moderate | 1 | [
[
[
472,
24,
999
]
],
[
[
472,
24,
286
],
[
286,
62,
999
]
],
[
[
472,
24,
1614
],
[
1614,
63,
999
]
],
[
[
472,
1,
1205
],
[
1205,
... | [
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
]
],
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
... | Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Thiethylperazine
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with N... |
DB09043 | DB11921 | 135 | 1,019 | [
"DDInter36",
"DDInter492"
] | Albiglutide | Deflazacort | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
135,
24,
1019
]
],
[
[
135,
63,
1072
],
[
1072,
23,
1019
]
],
[
[
135,
24,
192
],
[
192,
24,
1019
]
],
[
[
135,
63,
959
],
[
959,
... | [
[
[
"Albiglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Albiglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
],
[
... | Albiglutide may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid and Isoniazid may cause a minor interaction that can limit clinical effects when taken with Deflazacort
Albiglutide may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens a... |
DB00909 | DB09098 | 306 | 98 | [
"DDInter1971",
"DDInter1700"
] | Zonisamide | Somatrem | Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
306,
24,
98
]
],
[
[
306,
24,
159
],
[
159,
63,
98
]
],
[
[
306,
24,
609
],
[
609,
24,
98
]
],
[
[
306,
63,
1419
],
[
1419,
24,
... | [
[
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
... | Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin an... |
DB00095 | DB15035 | 66 | 503 | [
"DDInter623",
"DDInter1959"
] | Efalizumab | Zanubrutinib | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long... | Moderate | 1 | [
[
[
66,
24,
503
]
],
[
[
66,
24,
1430
],
[
1430,
24,
503
]
],
[
[
66,
63,
599
],
[
599,
24,
503
]
],
[
[
66,
24,
39
],
[
39,
25,
... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
... | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and... |
DB00108 | DB09122 | 1,066 | 1,613 | [
"DDInter1268",
"DDInter1409"
] | Natalizumab | Peginterferon beta-1a | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Major | 2 | [
[
[
1066,
25,
1613
]
],
[
[
1066,
24,
1627
],
[
1627,
24,
1613
]
],
[
[
1066,
25,
975
],
[
975,
63,
1613
]
],
[
[
1066,
25,
168
],
[
168,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Natalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
],
[
... | Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Natalizumab may lead to a major life threatening interaction when taken with Lurbinectedin and Lur... |
DB00031 | DB15035 | 20 | 503 | [
"DDInter1764",
"DDInter1959"
] | Tenecteplase | Zanubrutinib | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long... | Major | 2 | [
[
[
20,
25,
503
]
],
[
[
20,
24,
222
],
[
222,
24,
503
]
],
[
[
20,
25,
39
],
[
39,
25,
503
]
],
[
[
20,
24,
1018
],
[
1018,
25,
... | [
[
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sib... | Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Tenecteplase may lead to a major life threatening interaction when taken with Panobinostat and Panobinosta... |
DB00461 | DB00860 | 598 | 891 | [
"DDInter1254",
"DDInter1513"
] | Nabumetone | Prednisolone | Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a de... | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Moderate | 1 | [
[
[
598,
24,
891
]
],
[
[
598,
24,
175
],
[
175,
40,
891
]
],
[
[
598,
24,
167
],
[
167,
1,
891
]
],
[
[
598,
63,
251
],
[
251,
1,
... | [
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
]
],
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
... | Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisolone (Compound)
Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Predni... |
DB00758 | DB14006 | 1,347 | 972 | [
"DDInter413",
"DDInter370"
] | Clopidogrel | Choline salicylate | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Choline salicylate is an anti-inflammatory pain reliever agent that is related to aspirin. It is used to decrease swelling and to treat mild-moderate pain. It is used to treat arthritis in both children and adults. This medicine can also be used for fever . Choline Salicylate is the choline salt of salicylic acid, used... | Moderate | 1 | [
[
[
1347,
24,
972
]
],
[
[
1347,
64,
660
],
[
660,
23,
972
]
],
[
[
1347,
25,
379
],
[
379,
23,
972
]
],
[
[
1347,
23,
101
],
[
101,
... | [
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Choline salicylate"
]
],
[
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Esomeprazole"
],
[
... | Clopidogrel may lead to a major life threatening interaction when taken with Esomeprazole and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Choline salicylate
Clopidogrel may lead to a major life threatening interaction when taken with Rabeprazole and Rabeprazole may cause a... |
DB01114 | DB05812 | 272 | 1,374 | [
"DDInter362",
"DDInter8"
] | Chlorpheniramine | Abiraterone | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
272,
24,
1374
]
],
[
[
272,
6,
12523
],
[
12523,
45,
1374
]
],
[
[
272,
21,
28809
],
[
28809,
60,
1374
]
],
[
[
272,
74,
211
],
[
211,... | [
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Chlorpheniramine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v}... | Chlorpheniramine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Abiraterone (Compound)
Chlorpheniramine (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Abiraterone (Compound)
Chlorpheniramine (Compound) resembles Tolterodine (Compound) and Chlorpheniramine may cause a mo... |
DB00959 | DB09037 | 1,486 | 920 | [
"DDInter1191",
"DDInter1413"
] | Methylprednisolone | Pembrolizumab | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues and ... | Moderate | 1 | [
[
[
1486,
24,
920
]
],
[
[
1486,
40,
891
],
[
891,
24,
920
]
],
[
[
1486,
1,
175
],
[
175,
24,
920
]
],
[
[
1486,
25,
770
],
[
770,
... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pembrolizumab"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"... | Methylprednisolone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Pembrolizumab
Methylprednisolone (Compound) resembles Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate disease... |
DB00030 | DB13928 | 1,685 | 1,385 | [
"DDInter934",
"DDInter1660"
] | Insulin human | Semaglutide | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
1685,
24,
1385
]
],
[
[
1685,
23,
1103
],
[
1103,
23,
1385
]
],
[
[
1685,
24,
1154
],
[
1154,
24,
1385
]
],
[
[
1685,
24,
1399
],
[
13... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Insulin human",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
... | Insulin human may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Semaglutide
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide and Pa... |
DB00593 | DB12267 | 1,464 | 1,476 | [
"DDInter695",
"DDInter233"
] | Ethosuximide | Brigatinib | An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures. | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
1464,
24,
1476
]
],
[
[
1464,
24,
629
],
[
629,
24,
1476
]
],
[
[
1464,
63,
1184
],
[
1184,
24,
1476
]
],
[
[
1464,
24,
1619
],
[
1619... | [
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[... | Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakin... |
DB00497 | DB00662 | 828 | 717 | [
"DDInter1366",
"DDInter1873"
] | Oxycodone | Trimethobenzamide | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Moderate | 1 | [
[
[
828,
24,
717
]
],
[
[
828,
21,
29648
],
[
29648,
60,
717
]
],
[
[
828,
63,
1594
],
[
1594,
24,
717
]
],
[
[
828,
24,
506
],
[
506,
... | [
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Oxycodone",
"{u} (Compound) causes {v} (Side Effect)",
"Disorientation"
],
[
"Disorientation",
"{u} (Side ... | Oxycodone (Compound) causes Disorientation (Side Effect) and Disorientation (Side Effect) is caused by Trimethobenzamide (Compound)
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when tak... |
DB00444 | DB00773 | 63 | 896 | [
"DDInter1765",
"DDInter702"
] | Teniposide | Etoposide | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Moderate | 1 | [
[
[
63,
35,
896
]
],
[
[
63,
1,
11452
],
[
11452,
1,
896
]
],
[
[
63,
5,
11582
],
[
11582,
44,
896
]
],
[
[
63,
6,
7524
],
[
7524,
4... | [
[
[
"Teniposide",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
],
[
[
"Teniposide",
"{u} (Compound) resembles {v} (Compound)",
"Podofilox"
],
[
"P... | Teniposide (Compound) resembles Etoposide (Compound) and
Teniposide (Compound) resembles Podofilox (Compound) and Podofilox (Compound) resembles Etoposide (Compound)
Teniposide (Compound) treats lung cancer (Disease) and lung cancer (Disease) is treated by Etoposide (Compound)
Teniposide (Compound) binds CYP3A5 (Gene) ... |
DB00414 | DB00575 | 590 | 1,020 | [
"DDInter16",
"DDInter412"
] | Acetohexamide | Clonidine | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors. This activity is useful for the treatment of hypertension, severe pain, and ADHD.[L7237,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974. | Moderate | 1 | [
[
[
590,
24,
1020
]
],
[
[
590,
24,
1512
],
[
1512,
40,
1020
]
],
[
[
590,
24,
433
],
[
433,
63,
1020
]
],
[
[
590,
24,
251
],
[
251,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonidine"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac (Compound) resembles Clonidine (Compound)
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin and Ertugliflozin may cause a moderate interaction... |
DB01132 | DB06589 | 1,130 | 1,250 | [
"DDInter1472",
"DDInter1400"
] | Pioglitazone | Pazopanib | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
1130,
24,
1250
]
],
[
[
1130,
6,
15333
],
[
15333,
45,
1250
]
],
[
[
1130,
21,
29173
],
[
29173,
60,
1250
]
],
[
[
1130,
62,
307
],
[
... | [
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Pioglitazone",
"{u} (Compound) binds {v} (Gene)",
"SLCO1B1"
],
[
"SLCO1B1",
"{u} (Gene) is bound by {v} (Compou... | Pioglitazone (Compound) binds SLCO1B1 (Gene) and SLCO1B1 (Gene) is bound by Pazopanib (Compound)
Pioglitazone (Compound) causes Oedema peripheral (Side Effect) and Oedema peripheral (Side Effect) is caused by Pazopanib (Compound)
Pioglitazone may cause a minor interaction that can limit clinical effects when taken with... |
DB00575 | DB01143 | 1,020 | 923 | [
"DDInter412",
"DDInter65"
] | Clonidine | Amifostine | Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors. This activity is useful for the treatment of hypertension, severe pain, and ADHD.[L7237,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974. | A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia. | Moderate | 1 | [
[
[
1020,
24,
923
]
],
[
[
1020,
21,
28642
],
[
28642,
60,
923
]
],
[
[
1020,
24,
714
],
[
714,
24,
923
]
],
[
[
1020,
1,
1084
],
[
1084,
... | [
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifostine"
]
],
[
[
"Clonidine",
"{u} (Compound) causes {v} (Side Effect)",
"Shock"
],
[
"Shock",
"{u} (Side Effect) is caused by {v} ... | Clonidine (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Amifostine (Compound)
Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Amifostine
Clonidine ... |
DB00745 | DB09049 | 307 | 1,135 | [
"DDInter1236",
"DDInter1261"
] | Modafinil | Naloxegol | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron ac... | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Minor | 0 | [
[
[
307,
23,
1135
]
],
[
[
307,
25,
1406
],
[
1406,
62,
1135
]
],
[
[
307,
24,
971
],
[
971,
62,
1135
]
],
[
[
307,
62,
1424
],
[
1424,
... | [
[
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
]
],
[
[
"Modafinil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
],
[
"Neratinib",
... | Modafinil may lead to a major life threatening interaction when taken with Neratinib and Neratinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a m... |
DB00331 | DB09133 | 1,645 | 1,527 | [
"DDInter1164",
"DDInter965"
] | Metformin | Iothalamic acid | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | Iothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent. | Major | 2 | [
[
[
1645,
25,
1527
]
],
[
[
1645,
24,
863
],
[
863,
24,
1527
]
],
[
[
1645,
25,
1326
],
[
1326,
24,
1527
]
],
[
[
1645,
63,
228
],
[
228,
... | [
[
[
"Metformin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iothalamic acid"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiloride"
],
[
"Amilorid... | Metformin may cause a moderate interaction that could exacerbate diseases when taken with Amiloride and Amiloride may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid
Metformin may lead to a major life threatening interaction when taken with Diclofenamide and Diclofenamide may... |
DB00683 | DB12500 | 1,382 | 283 | [
"DDInter1212",
"DDInter714"
] | Midazolam | Fedratinib | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazola... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
1382,
24,
283
]
],
[
[
1382,
24,
351
],
[
351,
23,
283
]
],
[
[
1382,
63,
1419
],
[
1419,
24,
283
]
],
[
[
1382,
1,
481
],
[
481,
... | [
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
... | Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may... |
DB01221 | DB01364 | 1,190 | 22 | [
"DDInter1007",
"DDInter650"
] | Ketamine | Ephedrine | Ketamine is an NMDA receptor antagonist with a potent anesthetic effect. It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic... | Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. Ephedrine acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepine... | Moderate | 1 | [
[
[
1190,
24,
22
]
],
[
[
1190,
63,
1445
],
[
1445,
1,
22
]
],
[
[
1190,
6,
7390
],
[
7390,
45,
22
]
],
[
[
1190,
21,
28680
],
[
28680,
... | [
[
[
"Ketamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
]
],
[
[
"Ketamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
],
[
... | Ketamine may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine (Compound) resembles Ephedrine (Compound)
Ketamine (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Ephedrine (Compound)
Ketamine (Compound) causes Rash (Side Effect) and Rash (Side E... |
DB01075 | DB09034 | 1,376 | 1,313 | [
"DDInter569",
"DDInter1733"
] | Diphenhydramine | Suvorexant | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia. | Moderate | 1 | [
[
[
1376,
24,
1313
]
],
[
[
1376,
24,
649
],
[
649,
24,
1313
]
],
[
[
1376,
63,
530
],
[
530,
24,
1313
]
],
[
[
1376,
74,
100
],
[
100,
... | [
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]... | Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol ... |
DB00675 | DB01045 | 888 | 463 | [
"DDInter1744",
"DDInter1590"
] | Tamoxifen | Rifampicin | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Moderate | 1 | [
[
[
888,
24,
463
]
],
[
[
888,
63,
690
],
[
690,
40,
463
]
],
[
[
888,
6,
5912
],
[
5912,
45,
463
]
],
[
[
888,
24,
1264
],
[
1264,
... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
]
],
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifabutin"
],
[
... | Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin (Compound) resembles Rifampicin (Compound)
Tamoxifen (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) is bound by Rifampicin (Compound)
Tamoxifen may cause a moderate interaction that could exacerbate disease... |
DB08868 | DB11952 | 1,011 | 800 | [
"DDInter737",
"DDInter612"
] | Fingolimod | Duvelisib | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Major | 2 | [
[
[
1011,
25,
800
]
],
[
[
1011,
64,
310
],
[
310,
24,
800
]
],
[
[
1011,
25,
1476
],
[
1476,
63,
800
]
],
[
[
1011,
63,
267
],
[
267,
... | [
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Duvelisib"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} ... | Fingolimod may lead to a major life threatening interaction when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Fingolimod may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate int... |
DB00283 | DB00747 | 701 | 1,442 | [
"DDInter395",
"DDInter1647"
] | Clemastine | Scopolamine | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient ... | Moderate | 1 | [
[
[
701,
24,
1442
]
],
[
[
701,
24,
19
],
[
19,
24,
1442
]
],
[
[
701,
21,
28766
],
[
28766,
60,
1442
]
],
[
[
701,
24,
551
],
[
551,
... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Scopolamine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
[
... | Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine
Clemastine (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is caused by Scopolamine... |
DB06788 | DB09020 | 1,616 | 28 | [
"DDInter864",
"DDInter212"
] | Histrelin | Bisacodyl | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Moderate | 1 | [
[
[
1616,
24,
28
]
],
[
[
1616,
63,
739
],
[
739,
24,
28
]
],
[
[
1616,
64,
540
],
[
540,
24,
28
]
],
[
[
1616,
24,
938
],
[
938,
63... | [
[
[
"Histrelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Histrelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
],
[
... | Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Histrelin may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone may cau... |
DB00432 | DB09054 | 1,083 | 384 | [
"DDInter1868",
"DDInter905"
] | Trifluridine | Idelalisib | Trifluridine is a fluorinated pyrimidine nucleoside that is structurally related to [idoxuridine]. It is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus. It displays effective antiviral activity... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
1083,
24,
384
]
],
[
[
1083,
63,
58
],
[
58,
24,
384
]
],
[
[
1083,
24,
287
],
[
287,
63,
384
]
],
[
[
1083,
40,
1238
],
[
1238,
... | [
[
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[... | Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate ... |
DB01037 | DB06706 | 1,161 | 468 | [
"DDInter1653",
"DDInter985"
] | Selegiline | Isometheptene | A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual... | Isometheptene is a sympathomimetic drug that causes vasoconstriction. It is used for treating migraines and tension headaches. | Major | 2 | [
[
[
1161,
25,
468
]
],
[
[
1161,
63,
480
],
[
480,
24,
468
]
],
[
[
1161,
1,
633
],
[
633,
24,
468
]
],
[
[
1161,
24,
1148
],
[
1148,
... | [
[
[
"Selegiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isometheptene"
]
],
[
[
"Selegiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formote... | Selegiline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene
Selegiline (Compound) resembles Lisdexamfetamine (Compound) and Lisdexamfetamine may cause a moderate interac... |
DB01611 | DB13074 | 1,487 | 877 | [
"DDInter893",
"DDInter1110"
] | Hydroxychloroquine | Macimorelin | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
1487,
25,
877
]
],
[
[
1487,
63,
112
],
[
112,
23,
877
]
],
[
[
1487,
62,
1247
],
[
1247,
23,
877
]
],
[
[
1487,
63,
1191
],
[
1191,
... | [
[
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Hydroxychloroquine may cause a minor interaction that can limit clinical effects when taken with Su... |
DB00444 | DB01611 | 63 | 1,487 | [
"DDInter1765",
"DDInter893"
] | Teniposide | Hydroxychloroquine | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Moderate | 1 | [
[
[
63,
24,
1487
]
],
[
[
63,
21,
28658
],
[
28658,
60,
1487
]
],
[
[
63,
24,
723
],
[
723,
24,
1487
]
],
[
[
63,
63,
168
],
[
168,
... | [
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Teniposide",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) i... | Teniposide (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Hydroxychloroquine (Compound)
Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with H... |
DB00747 | DB09128 | 1,442 | 1,241 | [
"DDInter1647",
"DDInter231"
] | Scopolamine | Brexpiprazole | Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient ... | Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to [aripiprazole], brexpiprazole has different b... | Moderate | 1 | [
[
[
1442,
24,
1241
]
],
[
[
1442,
24,
407
],
[
407,
63,
1241
]
],
[
[
1442,
24,
543
],
[
543,
24,
1241
]
],
[
[
1442,
63,
1233
],
[
1233,
... | [
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexpiprazole"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
... | Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide ... |
DB00470 | DB01186 | 530 | 107 | [
"DDInter601",
"DDInter1430"
] | Dronabinol | Pergolide | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of Parkinson’s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic tr... | Moderate | 1 | [
[
[
530,
24,
107
]
],
[
[
530,
6,
8374
],
[
8374,
45,
107
]
],
[
[
530,
21,
28779
],
[
28779,
60,
107
]
],
[
[
530,
24,
832
],
[
832,
... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pergolide"
]
],
[
[
"Dronabinol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Dronabinol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pergolide (Compound)
Dronabinol (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Pergolide (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tr... |
DB08893 | DB11986 | 271 | 484 | [
"DDInter1229",
"DDInter648"
] | Mirabegron | Entrectinib | Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as [solifenacin] and [darifenacin], it lacks significa... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Minor | 0 | [
[
[
271,
23,
484
]
],
[
[
271,
23,
1320
],
[
1320,
24,
484
]
],
[
[
271,
62,
1478
],
[
1478,
24,
484
]
],
[
[
271,
23,
159
],
[
159,
... | [
[
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Entrectinib"
]
],
[
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Elagolix"
],
[
"... | Mirabegron may cause a minor interaction that can limit clinical effects when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ivacaftor and Ivacaftor may ... |
DB00146 | DB12147 | 160 | 241 | [
"DDInter265",
"DDInter661"
] | Calcifediol | Erdafitinib | The major circulating metabolite of vitamin D3 (cholecalciferol). It is produced in the liver and is the best indicator of the body's vitamin D stores. It is effective in the treatment of rickets and osteomalacia, both in azotemic and non-azotemic patients. Calcifediol also has mineralizing properties. | In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations... | Major | 2 | [
[
[
160,
25,
241
]
],
[
[
160,
24,
286
],
[
286,
25,
241
]
],
[
[
160,
25,
1196
],
[
1196,
25,
241
]
],
[
[
160,
36,
386
],
[
386,
2... | [
[
[
"Calcifediol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Erdafitinib"
]
],
[
[
"Calcifediol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
... | Calcifediol may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may lead to a major life threatening interaction when taken with Erdafitinib
Calcifediol may lead to a major life threatening interaction when taken with Doxercalciferol and Doxercalci... |
DB01087 | DB08875 | 1,520 | 1,618 | [
"DDInter1520",
"DDInter262"
] | Primaquine | Cabozantinib | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
1520,
25,
1618
]
],
[
[
1520,
62,
112
],
[
112,
23,
1618
]
],
[
[
1520,
24,
1032
],
[
1032,
63,
1618
]
],
[
[
1520,
63,
480
],
[
480,
... | [
[
[
"Primaquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Primaquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metroni... | Primaquine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol an... |
DB04868 | DB08880 | 478 | 1,510 | [
"DDInter1293",
"DDInter1771"
] | Nilotinib | Teriflunomide | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
478,
25,
1510
]
],
[
[
478,
25,
129
],
[
129,
63,
1510
]
],
[
[
478,
24,
1033
],
[
1033,
63,
1510
]
],
[
[
478,
63,
1088
],
[
1088,
... | [
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"... | Nilotinib may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cau... |
DB01284 | DB09263 | 1,042 | 1,436 | [
"DDInter1782",
"DDInter1399"
] | Tetracosactide | Patiromer | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Patiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015. Patiromer is supplied as patiromer sorbitex calcium which consists of the active moiety, patiromer, a non-absorbed potassium-binding polymer, and a calcium-sorbitol counterion. Each gram of patirome... | Moderate | 1 | [
[
[
1042,
24,
1436
]
],
[
[
1042,
63,
1645
],
[
1645,
24,
1436
]
],
[
[
1042,
24,
603
],
[
603,
63,
1436
]
],
[
[
1042,
24,
286
],
[
286,
... | [
[
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Patiromer"
]
],
[
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
],
... | Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Patiromer
Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrat... |
DB00862 | DB11827 | 1,005 | 433 | [
"DDInter1918",
"DDInter669"
] | Vardenafil | Ertugliflozin | Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction.[L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, ... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
1005,
24,
433
]
],
[
[
1005,
63,
521
],
[
521,
24,
433
]
],
[
[
1005,
24,
820
],
[
820,
24,
433
]
],
[
[
1005,
25,
609
],
[
609,
... | [
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
... | Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alim... |
DB01406 | DB11703 | 984 | 405 | [
"DDInter472",
"DDInter9"
] | Danazol | Acalabrutinib | A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Moderate | 1 | [
[
[
984,
24,
405
]
],
[
[
984,
63,
1324
],
[
1324,
24,
405
]
],
[
[
984,
24,
951
],
[
951,
24,
405
]
],
[
[
984,
24,
1297
],
[
1297,
... | [
[
[
"Danazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Danazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
... | Danazol may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Danazol may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and Palb... |
DB09570 | DB14444 | 1,480 | 151 | [
"DDInter1002",
"DDInter924"
] | Ixazomib | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Moderate | 1 | [
[
[
1480,
24,
151
]
],
[
[
1480,
63,
66
],
[
66,
24,
151
]
],
[
[
1480,
64,
375
],
[
375,
24,
151
]
],
[
[
1480,
24,
738
],
[
738,
2... | [
[
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Ixazomib",
"{u} may cause a moderate interaction that could exace... | Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Ixazomib may lead to a major life threa... |
DB00867 | DB01105 | 1,052 | 222 | [
"DDInter1606",
"DDInter1665"
] | Ritodrine | Sibutramine | Adrenergic beta-agonist used to control premature labor. | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
1052,
24,
222
]
],
[
[
1052,
63,
600
],
[
600,
23,
222
]
],
[
[
1052,
24,
609
],
[
609,
62,
222
]
],
[
[
1052,
25,
351
],
[
351,
... | [
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
... | Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Cla... |
DB00586 | DB01009 | 1,512 | 935 | [
"DDInter537",
"DDInter1009"
] | Diclofenac | Ketoprofen | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. | Moderate | 1 | [
[
[
1512,
24,
935
]
],
[
[
1512,
40,
253
],
[
253,
1,
935
]
],
[
[
1512,
24,
1523
],
[
1523,
40,
935
]
],
[
[
1512,
24,
1274
],
[
1274,
... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoprofen"
]
],
[
[
"Diclofenac",
"{u} (Compound) resembles {v} (Compound)",
"Mefenamic acid"
],
[
"Mefenamic acid",
"{u} (Compound) ... | Diclofenac (Compound) resembles Mefenamic acid (Compound) and Mefenamic acid (Compound) resembles Ketoprofen (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol (Compound) resembles Ketoprofen (Compound)
Diclofenac may cause a moderate interactio... |
DB00393 | DB08946 | 854 | 512 | [
"DDInter1295",
"DDInter962"
] | Nimodipine | Iopanoic acid | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction ... | Iopanoic acid contains iodine and is useful as a contrast medium in cholecystography. | Moderate | 1 | [
[
[
854,
24,
512
]
],
[
[
854,
1,
1428
],
[
1428,
24,
512
]
],
[
[
854,
24,
1527
],
[
1527,
63,
512
]
],
[
[
854,
24,
1431
],
[
1431,
... | [
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopanoic acid"
]
],
[
[
"Nimodipine",
"{u} (Compound) resembles {v} (Compound)",
"Isradipine"
],
[
"Isradipine",
"{u} may cause a mode... | Nimodipine (Compound) resembles Isradipine (Compound) and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Iopanoic acid
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid and Iothalamic acid may cause a moderate interacti... |
DB00465 | DB01097 | 886 | 1,377 | [
"DDInter1010",
"DDInter1033"
] | Ketorolac | Leflunomide | Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, men... | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
886,
25,
1377
]
],
[
[
886,
21,
29231
],
[
29231,
60,
1377
]
],
[
[
886,
25,
126
],
[
126,
24,
1377
]
],
[
[
886,
24,
959
],
[
959,
... | [
[
[
"Ketorolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Ketorolac",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac disorder"
],
[
"Cardiac disorder",
"{u} (Side Effect) is caused... | Ketorolac (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Leflunomide (Compound)
Ketorolac may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
K... |
DB00009 | DB00727 | 1,271 | 685 | [
"DDInter56",
"DDInter1304"
] | Alteplase | Nitroglycerin | Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplas... | Nitroglycerin, also known as glyceryl trinitrate, is an organic nitrate and a vasodilating agent that was first discovered in 1847. Originally used to dynamite, its antianginal effects were identified in the late 1860s after it produced headaches in factory workers while workers with angina pectoris or heart failure ex... | Moderate | 1 | [
[
[
1271,
24,
685
]
],
[
[
1271,
24,
1479
],
[
1479,
62,
685
]
],
[
[
1271,
24,
885
],
[
885,
63,
685
]
],
[
[
1271,
24,
1061
],
[
1061,
... | [
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitroglycerin"
]
],
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
... | Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Nitroglycerin
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Ep... |
DB00813 | DB09330 | 704 | 985 | [
"DDInter722",
"DDInter1352"
] | Fentanyl | Osimertinib | Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
704,
24,
985
]
],
[
[
704,
24,
1478
],
[
1478,
24,
985
]
],
[
[
704,
63,
134
],
[
134,
24,
985
]
],
[
[
704,
25,
1040
],
[
1040,
... | [
[
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
... | Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbin... |
DB00563 | DB01042 | 663 | 1,307 | [
"DDInter1174",
"DDInter1144"
] | Methotrexate | Melphalan | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-con... | Moderate | 1 | [
[
[
663,
24,
1307
]
],
[
[
663,
25,
848
],
[
848,
40,
1307
]
],
[
[
663,
5,
11579
],
[
11579,
44,
1307
]
],
[
[
663,
7,
3151
],
[
3151,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofe... | Methotrexate may lead to a major life threatening interaction when taken with Ibuprofen and Ibuprofen (Compound) resembles Melphalan (Compound)
Methotrexate (Compound) treats breast cancer (Disease) and breast cancer (Disease) is treated by Melphalan (Compound)
Methotrexate (Compound) upregulates DDB2 (Gene) and DDB2 (... |
DB01116 | DB01168 | 601 | 1,053 | [
"DDInter1872",
"DDInter1526"
] | Trimethaphan | Procarbazine | A nicotinic antagonist that has been used as a ganglionic blocker in hypertension, as an adjunct to anesthesia, and to induce hypotension during surgery. | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Moderate | 1 | [
[
[
601,
24,
1053
]
],
[
[
601,
63,
1648
],
[
1648,
24,
1053
]
],
[
[
601,
40,
762
],
[
762,
63,
1053
]
],
[
[
601,
24,
885
],
[
885,
... | [
[
[
"Trimethaphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Trimethaphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
... | Trimethaphan may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Trimethaphan (Compound) resembles Bepridil (Compound) and Bepridil may cause a moderate interaction that c... |
DB00434 | DB01209 | 13 | 1,359 | [
"DDInter459",
"DDInter531"
] | Cyproheptadine | Dezocine | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Dezocine is a partial opiate drug and is used for pain management. Dezocine is a very effective alternative to fentanyl when administered during outpatient laparoscopy, although is associated with an increased incidence of postoperative nausea. | Moderate | 1 | [
[
[
13,
24,
1359
]
],
[
[
13,
24,
234
],
[
234,
1,
1359
]
],
[
[
13,
24,
717
],
[
717,
24,
1359
]
],
[
[
13,
63,
1594
],
[
1594,
24,... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dezocine"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentazocine"
],
... | Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Pentazocine and Pentazocine (Compound) resembles Dezocine (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide and Trimethobenzamide may cause a moderate ... |
DB00289 | DB06595 | 847 | 1,491 | [
"DDInter132",
"DDInter1214"
] | Atomoxetine | Midostaurin | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve develop... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
847,
24,
1491
]
],
[
[
847,
23,
112
],
[
112,
23,
1491
]
],
[
[
847,
24,
888
],
[
888,
24,
1491
]
],
[
[
847,
24,
657
],
[
657,
... | [
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Atomoxetine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Atomoxetine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Ta... |
DB00443 | DB00582 | 251 | 1,622 | [
"DDInter195",
"DDInter1946"
] | Betamethasone | Voriconazole | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Moderate | 1 | [
[
[
251,
24,
1622
]
],
[
[
251,
6,
8374
],
[
8374,
45,
1622
]
],
[
[
251,
7,
5774
],
[
5774,
46,
1622
]
],
[
[
251,
21,
28997
],
[
28997,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
]
],
[
[
"Betamethasone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Com... | Betamethasone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Voriconazole (Compound)
Betamethasone (Compound) upregulates SELL (Gene) and SELL (Gene) is upregulated by Voriconazole (Compound)
Betamethasone (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is cause... |
DB00059 | DB00398 | 1,560 | 79 | [
"DDInter1404",
"DDInter1702"
] | Pegaspargase | Sorafenib | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Moderate | 1 | [
[
[
1560,
24,
79
]
],
[
[
1560,
24,
292
],
[
292,
40,
79
]
],
[
[
1560,
24,
549
],
[
549,
62,
79
]
],
[
[
1560,
24,
126
],
[
126,
63... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
],
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib and Regorafenib (Compound) resembles Sorafenib (Compound)
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a minor interaction th... |
DB00375 | DB00741 | 1,037 | 167 | [
"DDInter433",
"DDInter885"
] | Colestipol | Hydrocortisone | Bile acid sequestrants like colestipol have been in use since the 1970s.[FDA Label, F4555, F4567, L6262] And even though such an agent may very well be useful in reducing elevated cholesterol levels and decreasing the risk for atherosclerotic vascular disease due to hypercholesterolemia, colestipol is still generally o... | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Moderate | 1 | [
[
[
1037,
24,
167
]
],
[
[
1037,
24,
1220
],
[
1220,
40,
167
]
],
[
[
1037,
24,
870
],
[
870,
1,
167
]
],
[
[
1037,
21,
28900
],
[
28900,
... | [
[
[
"Colestipol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Colestipol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Colestipol may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Hydrocortisone (Compound)
Colestipol may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Hy... |
DB00005 | DB08901 | 1,057 | 1,468 | [
"DDInter687",
"DDInter1492"
] | Etanercept | Ponatinib | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Major | 2 | [
[
[
1057,
25,
1468
]
],
[
[
1057,
25,
478
],
[
478,
24,
1468
]
],
[
[
1057,
24,
987
],
[
987,
63,
1468
]
],
[
[
1057,
24,
651
],
[
651,
... | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may ... | Etanercept may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live... |
DB00307 | DB00802 | 1,101 | 1,322 | [
"DDInter202",
"DDInter43"
] | Bexarotene | Alfentanil | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. | Moderate | 1 | [
[
[
1101,
24,
1322
]
],
[
[
1101,
24,
704
],
[
704,
1,
1322
]
],
[
[
1101,
6,
8374
],
[
8374,
45,
1322
]
],
[
[
1101,
21,
29118
],
[
29118... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alfentanil"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fentanyl"
],
[
... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and Fentanyl (Compound) resembles Alfentanil (Compound)
Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Alfentanil (Compound)
Bexarotene (Compound) causes Tachycardia (Side Effect) and Tachycardia... |
DB00015 | DB01125 | 582 | 279 | [
"DDInter1585",
"DDInter98"
] | Reteplase | Anisindione | Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids p... | Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagu... | Major | 2 | [
[
[
582,
25,
279
]
],
[
[
582,
24,
1595
],
[
1595,
24,
279
]
],
[
[
582,
24,
557
],
[
557,
63,
279
]
],
[
[
582,
25,
1564
],
[
1564,
... | [
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anisindione"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Collagenase clostridium histolyticum"
]... | Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Collagenase clostridium histolyticum and Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Reteplase may cause a moderate interaction that could exacer... |
DB00196 | DB00349 | 600 | 902 | [
"DDInter743",
"DDInter401"
] | Fluconazole | Clobazam | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Clobazam belongs to the 1,5-benzodiazepine class of drugs and is marketed under different names, Onfi, Frisium, Urbanyl, and others.. Clobazam was first synthesized in 1966 and first published in 1969, following the incidental synthesis and discovery of the first benzodiazepine chlordiazepoxide in the 1950s. Unlike old... | Moderate | 1 | [
[
[
600,
24,
902
]
],
[
[
600,
25,
1382
],
[
1382,
1,
902
]
],
[
[
600,
24,
1237
],
[
1237,
1,
902
]
],
[
[
600,
6,
4973
],
[
4973,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clobazam"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midazolam"
],
[
"Midazolam",... | Fluconazole may lead to a major life threatening interaction when taken with Midazolam and Midazolam (Compound) resembles Clobazam (Compound)
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine (Compound) resembles Clobazam (Compound)
Fluconazole (Co... |
DB00026 | DB00065 | 1,184 | 581 | [
"DDInter94",
"DDInter923"
] | Anakinra | Infliximab | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions . Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory... | Major | 2 | [
[
[
1184,
25,
581
]
],
[
[
1184,
23,
1461
],
[
1461,
62,
581
]
],
[
[
1184,
24,
1336
],
[
1336,
63,
581
]
],
[
[
1184,
25,
1137
],
[
1137,... | [
[
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
]
],
[
[
"Anakinra",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
... | Anakinra may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Infliximab
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Etonogestrel and Etonogestrel m... |
DB11791 | DB12500 | 785 | 283 | [
"DDInter287",
"DDInter714"
] | Capmatinib | Fedratinib | Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or ov... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
785,
24,
283
]
],
[
[
785,
63,
351
],
[
351,
23,
283
]
],
[
[
785,
63,
1419
],
[
1419,
24,
283
]
],
[
[
785,
24,
971
],
[
971,
2... | [
[
[
"Capmatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Capmatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
... | Capmatinib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Capmatinib may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib m... |
DB00331 | DB01238 | 1,645 | 673 | [
"DDInter1164",
"DDInter118"
] | Metformin | Aripiprazole | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Moderate | 1 | [
[
[
1645,
24,
673
]
],
[
[
1645,
24,
1630
],
[
1630,
1,
673
]
],
[
[
1645,
18,
17480
],
[
17480,
57,
673
]
],
[
[
1645,
21,
28792
],
[
287... | [
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"
],
[
... | Metformin may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine (Compound) resembles Aripiprazole (Compound)
Metformin (Compound) downregulates ENOPH1 (Gene) and ENOPH1 (Gene) is downregulated by Aripiprazole (Compound)
Metformin (Compound) causes Gastrointestinal... |
DB00530 | DB01263 | 1,195 | 859 | [
"DDInter667",
"DDInter1494"
] | Erlotinib | Posaconazole | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)... | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Moderate | 1 | [
[
[
1195,
24,
859
]
],
[
[
1195,
6,
4973
],
[
4973,
45,
859
]
],
[
[
1195,
21,
28762
],
[
28762,
60,
859
]
],
[
[
1195,
63,
1101
],
[
1101... | [
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Erlotinib",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Erlotinib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Posaconazole (Compound)
Erlotinib (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Posaconazole (Compound)
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarot... |
DB00196 | DB00559 | 600 | 152 | [
"DDInter743",
"DDInter223"
] | Fluconazole | Bosentan | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Moderate | 1 | [
[
[
600,
24,
152
]
],
[
[
600,
6,
6017
],
[
6017,
45,
152
]
],
[
[
600,
21,
29402
],
[
29402,
60,
152
]
],
[
[
600,
24,
608
],
[
608,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosentan"
]
],
[
[
"Fluconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",... | Fluconazole (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Bosentan (Compound)
Fluconazole (Compound) causes Hepatobiliary disease (Side Effect) and Hepatobiliary disease (Side Effect) is caused by Bosentan (Compound)
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken w... |
DB06317 | DB11988 | 1,626 | 270 | [
"DDInter630",
"DDInter1321"
] | Elotuzumab | Ocrelizumab | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family... | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
1626,
24,
270
]
],
[
[
1626,
24,
1060
],
[
1060,
63,
270
]
],
[
[
1626,
63,
134
],
[
134,
24,
270
]
],
[
[
1626,
24,
713
],
[
713,
... | [
[
[
"Elotuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Elotuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
],... | Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Vino... |
DB00328 | DB08899 | 831 | 129 | [
"DDInter921",
"DDInter649"
] | Indomethacin | Enzalutamide | Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlor... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
831,
24,
129
]
],
[
[
831,
6,
1829
],
[
1829,
45,
129
]
],
[
[
831,
21,
28703
],
[
28703,
60,
129
]
],
[
[
831,
25,
1510
],
[
1510,
... | [
[
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Indomethacin",
"{u} (Compound) binds {v} (Gene)",
"ALB"
],
[
"ALB",
"{u} (Gene) is bound by {v} (Compound)",... | Indomethacin (Compound) binds ALB (Gene) and ALB (Gene) is bound by Enzalutamide (Compound)
Indomethacin (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound)
Indomethacin may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide ... |
DB01001 | DB12825 | 688 | 1,375 | [
"DDInter1632",
"DDInter1032"
] | Salbutamol | Lefamulin | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Moderate | 1 | [
[
[
688,
24,
1375
]
],
[
[
688,
62,
112
],
[
112,
23,
1375
]
],
[
[
688,
24,
659
],
[
659,
24,
1375
]
],
[
[
688,
62,
870
],
[
870,
... | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Salbutamol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Salbutamol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lefamulin
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilan... |
DB11689 | DB11837 | 321 | 1,297 | [
"DDInter1659",
"DDInter1351"
] | Selumetinib | Osilodrostat | Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway. Results from clinical trials investigating ea... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
321,
24,
1297
]
],
[
[
321,
24,
1320
],
[
1320,
63,
1297
]
],
[
[
321,
63,
353
],
[
353,
24,
1297
]
],
[
[
321,
64,
597
],
[
597,
... | [
[
[
"Selumetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Selumetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
... | Selumetinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Selumetinib may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Gris... |
DB01001 | DB01268 | 688 | 1,151 | [
"DDInter1632",
"DDInter1731"
] | Salbutamol | Sunitinib | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
688,
24,
1151
]
],
[
[
688,
6,
8374
],
[
8374,
45,
1151
]
],
[
[
688,
21,
28868
],
[
28868,
60,
1151
]
],
[
[
688,
23,
1247
],
[
1247,... | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Salbutamol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Salbutamol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sunitinib (Compound)
Salbutamol (Compound) causes Stomatitis (Side Effect) and Stomatitis (Side Effect) is caused by Sunitinib (Compound)
Salbutamol may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and ... |
DB11601 | DB11817 | 1,270 | 1,259 | [
"DDInter1889",
"DDInter165"
] | Tuberculin purified protein derivative | Baricitinib | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Moderate | 1 | [
[
[
1270,
24,
1259
]
],
[
[
1270,
63,
384
],
[
384,
25,
1259
]
],
[
[
1270,
24,
1619
],
[
1619,
64,
1259
]
],
[
[
1270,
24,
351
],
[
351,
... | [
[
[
"Tuberculin purified protein derivative",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Baricitinib"
]
],
[
[
"Tuberculin purified protein derivative",
"{u} may cause a moderate interaction that could exacerbate diseases... | Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Baricitinib
Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate dise... |
DB00834 | DB06699 | 932 | 774 | [
"DDInter1215",
"DDInter493"
] | Mifepristone | Degarelix | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Major | 2 | [
[
[
932,
25,
774
]
],
[
[
932,
64,
521
],
[
521,
1,
774
]
],
[
[
932,
21,
29232
],
[
29232,
60,
774
]
],
[
[
932,
23,
112
],
[
112,
... | [
[
[
"Mifepristone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Degarelix"
]
],
[
[
"Mifepristone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} ... | Mifepristone may lead to a major life threatening interaction when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Mifepristone (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Degarelix (Compound)
Mifepristone may cause a minor interaction that can limit c... |
DB11730 | DB12457 | 351 | 1,180 | [
"DDInter1588",
"DDInter1598"
] | Ribociclib | Rimegepant | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several p... | Moderate | 1 | [
[
[
351,
24,
1180
]
],
[
[
351,
25,
1619
],
[
1619,
24,
1180
]
],
[
[
351,
63,
1419
],
[
1419,
24,
1180
]
],
[
[
351,
23,
283
],
[
283,
... | [
[
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rimegepant"
]
],
[
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",... | Ribociclib may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant
Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a mode... |
DB01001 | DB01168 | 688 | 1,053 | [
"DDInter1632",
"DDInter1526"
] | Salbutamol | Procarbazine | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Moderate | 1 | [
[
[
688,
24,
1053
]
],
[
[
688,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
688,
24,
246
],
[
246,
23,
1053
]
],
[
[
688,
63,
739
],
[
739,
... | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Salbutamol",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caus... | Salbutamol (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Gatifloxacin and Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Proca... |
DB00280 | DB01075 | 494 | 1,376 | [
"DDInter575",
"DDInter569"
] | Disopyramide | Diphenhydramine | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Moderate | 1 | [
[
[
494,
24,
1376
]
],
[
[
494,
40,
649
],
[
649,
63,
1376
]
],
[
[
494,
25,
11
],
[
11,
1,
1376
]
],
[
[
494,
24,
128
],
[
128,
24,... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Disopyramide",
"{u} (Compound) resembles {v} (Compound)",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause ... | Disopyramide (Compound) resembles Clofedanol (Compound) and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Disopyramide may lead to a major life threatening interaction when taken with Toremifene and Toremifene (Compound) resembles Diphenhydramine (Compound)
D... |
DB00783 | DB00990 | 1,438 | 1,547 | [
"DDInter679",
"DDInter705"
] | Estradiol | Exemestane | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vag... | Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition. | Moderate | 1 | [
[
[
1438,
24,
1547
]
],
[
[
1438,
24,
891
],
[
891,
40,
1547
]
],
[
[
1438,
1,
380
],
[
380,
24,
1547
]
],
[
[
1438,
63,
1573
],
[
1573,
... | [
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exemestane"
]
],
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
... | Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone (Compound) resembles Exemestane (Compound)
Estradiol (Compound) resembles Conjugated estrogens (Compound) and Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when ... |
DB00850 | DB09268 | 1,630 | 1,662 | [
"DDInter1432",
"DDInter1464"
] | Perphenazine | Picosulfuric acid | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
1630,
24,
1662
]
],
[
[
1630,
24,
484
],
[
484,
63,
1662
]
],
[
[
1630,
25,
1618
],
[
1618,
24,
1662
]
],
[
[
1630,
63,
73
],
[
73,
... | [
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
... | Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Perphenazine may lead to a major life threatening interaction when taken with Cabozantinib and Caboza... |
DB00912 | DB01175 | 473 | 318 | [
"DDInter1581",
"DDInter672"
] | Repaglinide | Escitalopram | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Moderate | 1 | [
[
[
473,
24,
318
]
],
[
[
473,
63,
1230
],
[
1230,
1,
318
]
],
[
[
473,
6,
8374
],
[
8374,
45,
318
]
],
[
[
473,
21,
28850
],
[
28850,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Repaglinide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Escitalopram (Compound)
Repaglinide (Compound) causes Back pain (Side Effect) and Ba... |
DB01236 | DB06699 | 679 | 774 | [
"DDInter1664",
"DDInter493"
] | Sevoflurane | Degarelix | Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 199... | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Moderate | 1 | [
[
[
679,
24,
774
]
],
[
[
679,
63,
521
],
[
521,
1,
774
]
],
[
[
679,
21,
29232
],
[
29232,
60,
774
]
],
[
[
679,
62,
112
],
[
112,
... | [
[
[
"Sevoflurane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Sevoflurane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
... | Sevoflurane may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Sevoflurane (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Degarelix (Compound)
Sevoflurane may cause a minor interaction that... |
DB00601 | DB06706 | 453 | 468 | [
"DDInter1073",
"DDInter985"
] | Linezolid | Isometheptene | Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the init... | Isometheptene is a sympathomimetic drug that causes vasoconstriction. It is used for treating migraines and tension headaches. | Major | 2 | [
[
[
453,
25,
468
]
],
[
[
453,
24,
480
],
[
480,
24,
468
]
],
[
[
453,
24,
144
],
[
144,
63,
468
]
],
[
[
453,
25,
222
],
[
222,
24,... | [
[
[
"Linezolid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isometheptene"
]
],
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formotero... | Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Oloda... |
DB00754 | DB01041 | 157 | 770 | [
"DDInter696",
"DDInter1789"
] | Ethotoin | Thalidomide | Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to ... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
157,
24,
770
]
],
[
[
157,
6,
10215
],
[
10215,
45,
770
]
],
[
[
157,
21,
28714
],
[
28714,
60,
770
]
],
[
[
157,
24,
609
],
[
609,
... | [
[
[
"Ethotoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Ethotoin",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
... | Ethotoin (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Thalidomide (Compound)
Ethotoin (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Thalidomide (Compound)
Ethotoin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clar... |
DB00348 | DB06212 | 254 | 165 | [
"DDInter1300",
"DDInter1833"
] | Nitisinone | Tolvaptan | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009. | Moderate | 1 | [
[
[
254,
24,
165
]
],
[
[
254,
24,
1080
],
[
1080,
1,
165
]
],
[
[
254,
21,
28771
],
[
28771,
60,
165
]
],
[
[
254,
24,
1450
],
[
1450,
... | [
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolvaptan"
]
],
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conivaptan"
],
[
... | Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Conivaptan and Conivaptan (Compound) resembles Tolvaptan (Compound)
Nitisinone (Compound) causes Respiratory failure (Side Effect) and Respiratory failure (Side Effect) is caused by Tolvaptan (Compound)
Nitisinone may cause a mod... |
DB06764 | DB09080 | 1,090 | 144 | [
"DDInter1787",
"DDInter1331"
] | Tetryzoline (nasal) | Olodaterol | Tetryzoline is a member of imidazolines and a carboxamidine. It has a role as a sympathomimetic agent and a nasal decongestant. It is a conjugate base of a tetryzoline(1+). | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
1090,
24,
144
]
],
[
[
1090,
63,
1290
],
[
1290,
24,
144
]
],
[
[
1090,
24,
1663
],
[
1663,
63,
144
]
],
[
[
1090,
24,
41
],
[
41,
... | [
[
[
"Tetryzoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Tetryzoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midodrine"
],
[
... | Tetryzoline may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Tetryzoline may cause a moderate interaction that could exacerbate diseases when taken with Midodrine and Midodrine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Tetryzolin... |
DB00313 | DB00835 | 556 | 100 | [
"DDInter1913",
"DDInter245"
] | Valproic acid | Brompheniramine | Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investig... | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
556,
24,
100
]
],
[
[
556,
24,
832
],
[
832,
24,
100
]
],
[
[
556,
24,
649
],
[
649,
63,
100
]
],
[
[
556,
6,
8374
],
[
8374,
45... | [
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
... | Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Cl... |
DB09054 | DB12941 | 384 | 466 | [
"DDInter905",
"DDInter481"
] | Idelalisib | Darolutamide | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate canc... | Moderate | 1 | [
[
[
384,
24,
466
]
],
[
[
384,
63,
1622
],
[
1622,
23,
466
]
],
[
[
384,
64,
1623
],
[
1623,
23,
466
]
],
[
[
384,
25,
351
],
[
351,
... | [
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
],
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
],
... | Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole and Voriconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Idelalisib may lead to a major life threatening interaction when taken with Isavuconazonium and Isavuconazon... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.